My research focuses on developing improved therapies for patients with sarcomas and related diseases. In order to create new opportunities for clinical investigations I have been contacting companies with interesting agents, which may not have considered for use in sarcomas, a rare and so often orphaned area for research. I am working to establish collaborative clinical studies, first with pilot studies for the multi-modality sarcoma group here at MGH, then for phase II studies through the Joint Venture with the other Dana Farber/Harvard hospitals, and via affiliations with CALGB and RTOG. More recently associations with Memorial Sloan Kettering, with the S.A.R.C. group and with ACOSOG are providing an extension of that network, permitting phase III trials as well. I will continue participating in various phase I and II trials for sarcoma patients or for those whose presentations may be similar, including those with lymphoma of bone and myeloma. My goal is to provide experimental options for patients with the various types of sarcomas in whatever circumstance standard therapies still seem inadequate.